MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext Aeromonas hydrophila septicemia in a patient with chronic active hepatitis

Segasothy M, Jamal F

Med J Malaysia, 1982 Sep;37(3):211-2.
PMID: 7176998
Matched MeSH terms: Hepatitis, Chronic/complications*
Fulltext Anti-hepatitis A seroprevalence among chronic viral hepatitis patients in Kelantan, Malaysia

Ahmad F, Hamzah NA, Mustaffa N, Gan SH

World J Gastroenterol, 2011 Sep 28;17(36):4130-4.
PMID: 22039329 DOI: 10.3748/wjg.v17.i36.4130

To determine the seroprevalence of anti-hepatitis A virus (HAV) antibodies in patients with chronic liver disease (CLD) and to justify the need for hepatitis A vaccination.

Matched MeSH terms: Hepatitis, Chronic/blood*; Hepatitis, Chronic/immunology*; Hepatitis, Chronic/epidemiology; Hepatitis, Chronic/prevention & control
Improving the hepatitis cascade: assessing hepatitis testing and its management in primary health care in China

Wong WCW, Lo YR, Jiang S, Peng M, Zhu S, Kidd MR, et al.

Fam Pract, 2018 12 12;35(6):731-737.
PMID: 29741661 DOI: 10.1093/fampra/cmy032

Objective: The study aimed to decentralize hepatitis testing and management services to primary care in China.
Methods: A nationwide representative provider survey amongst community health centres (CHCs) using randomized stratified sampling methods was conducted between September and December 2015. One hundred and eighty CHCs and frontline primary care practitioners from 20 cities across three administrative regions of Western, Central and Eastern China were invited to participate.
Results: One hundred and forty-nine clinicians-in-charge (79%), 1734 doctors and 1846 nurses participated (86%). Majority of CHCs (80%, 95% CI: 74-87) offered hepatitis B testing, but just over half (55%, 95% CI: 46-65) offered hepatitis C testing. The majority of doctors (87%) and nurses (85%) felt that there were benefits for providing hepatitis testing at CHCs. The major barriers for not offering hepatitis testing were lack of training (54%) and financial support (23%). Multivariate analysis showed that the major determinants for CHCs to offer hepatitis B and C testing were the number of nurses (AOR 1.1) and written policies for hepatitis B diagnosis (AOR 12.7-27.1), and for hepatitis B the availability of reproductive health service.
Conclusions: Primary care providers in China could play a pivotal role in screening, diagnosing and treating millions of people with chronic hepatitis B and C in China.

Matched MeSH terms: Hepatitis, Chronic/diagnosis*; Hepatitis, Chronic/epidemiology; Hepatitis, Chronic/therapy*
Serobiological features and risk factors of hepatitis C virus infection in multiply transfused thalassaemia patients

Ghazali, F., Jamal, R., Zakaria, S.Z., Ismail, Z.H., Malik, Y.

Malaysian Journal of Paediatrics and Child Health, 1998;10(2):14-18.
MyJurnal

The two vital aspects of treatment for patients with tha-lassaemia are regular blood transfusions and iron chela-tion therapy. Unfortunately, the use of blood transfu-sions exposes these patients to the risks of acquiring transfusion related viral infections such as hepatitis C. Patients who acquire the hepatitis C virus (HCV) may develop chronic hepatitis and later on hepatocellular carcinoma. Hence, patients with thalassaemia should be regularly screened for the presence of HCV. We report here the results of a cross-sectional study conducted in a typical day-care centre for thalassaemics at the Hospital Universiti Kebangsaan Malaysia, involving 85 multiply transfused patients. We found that 19 patients (22.4%) were seropositive for HCV and two of them had positive HCV-RNA. Those who had started receiv-ing their transfusions before 1995, i.e. the year routine screening for HCV amongst blood donors were com-menced, and those who received transfusions 2-4 week-ly had a significantly higher risk of acquiring HCV infection.

Matched MeSH terms: Hepatitis, Chronic
Fulltext Hepatitis C--the Malaysian story

Sinniah M, Ooi BG

Singapore Med J, 1993 Apr;34(2):132-4.
PMID: 8266152

We studied the presence of Hepatitis C Virus (HCV) antibodies in a defined Malaysian population and examined the association, if any, between HCV and the Hepatitis B Virus (HBV), using sensitive recombinant DNA second generation Enzyme Immunoassay (EIA) test kits. This sero-prevalence study comprised 1,434 sera from eleven distinct groups comprising intravenous drug users (IVDU), haemophiliacs, male homosexuals, female prostitutes, healthy blood donors, staff of dialysis unit and laboratory personnel, chronic renal failure patients undergoing dialysis (CRFD), patients with liver cirrhosis, chronic active hepatitis, chronic persistent hepatitis and primary liver cancer. Except in laboratory personnel and dialysis staff, HCV antibodies were detected in each group of patients ranging from 3% in blood donors to 85% in IVDU. The main modes of HCV transmission identified were parenteral drug use, transfusion and/or dialysis related. The HBV was found to be the major viral etiological agent in 75% of chronic liver disease (CLD); while in 10% of cases both HCV and HBV were detected. HCV was implicated as the sole viral agent in only a small proportion (1.5%) of patients with chronic liver disease.

Matched MeSH terms: Hepatitis, Chronic/microbiology